You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
The ‘parkinsonian heart’: a diagnostic and prognostic tool
  1. África Muxí1,2,3
  1. 1Nuclear Medicine Department, Hospital Clínic Barcelona, Barcelona, Spain
  2. 2Institut d'Investigacions Biomèdiques August Pí i Sunyer (IDIBAPS), Barcelona, Spain
  3. 3Universitat de Barcelona, Barcelona, Spain
  1. Correspondence to Dr África Muxí, Nuclear Medicine Department, Hospital Clínic, Villarroel 170, Barcelona 08036, Spain; amuxi{at}clinic.ub.es

https://doi.org/10.1136/jnnp-2015-310785

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In their JNNP paper Tsujikawa et al characterise Parkinson disease (PD) at the early stages in 70 patients, according to 123I-meta-iodobenzylguanidine (mIBG) myocardial scintigraphic, and report its chronological changes (mean follow-up 3 years) with its symptoms relationship.1

    123I-mIBG is a Norepinefrine (NE) analogue that competes with NE for the same transporter mechanism of postganglionar adrenergic neurons. The uptake of mIBG into neurons is achieved mainly through the uptake-1 mechanism, a high affinity homeostatic system responsible for the reuptake of NE. Receptors for NE or mIBG are located on the synapse in sympathetic terminal nerve axons; once in the axon, the tracer is transported in the axoplasm to …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    • Short sentence: 123I-meta-iodobenzylguanidine (mIBG) myocardial scintigraphy: A Molecular Imaging technique to improve the understanding and the characterization of the Parkinson disease.

    Linked Articles